hellotayssir/FinQA_TAT-QA_financial_finetuning_dataset huggingface dataset:
Summary of Results
The following table sets forth, for the periods indicated, certain key operating results and other financial information (in thousands, except per share data):
Table:
 |  | Fiscal Year Ended August 31, | 
 | 2019 | 2018 | 2017
Net revenue | $25,282,320 | $22,095,416 | $19,063,121
Gross profit | $1,913,401 | $1,706,792 | $1,545,643
Operating income | $701,356 | $542,153 | $410,230
Net income attributable to Jabil Inc | $287,111 | $86,330 | $129,090
Earnings per share – basic | $1.85 | $0.50 | $0.71
Earnings per share – diluted | $1.81 | $0.49 | $0.69


Question: What was the gross profit in 2018?
Answer: $1,706,792
The following is a summary of amounts reclassified from AOCI for the years ended June 30, 2019 and 2018:
(a) Amounts in parentheses indicate debits to income/loss.
(b) These AOCI components are included in the computation of net periodic benefit cost (see Note 11 for additional details).
Table:
 |  | Amount Reclassified from AOCI | 
 |  | Years Ended June 30, | 
($ in millions) (a) | Location of gain (loss) | 2019 | 2018
Details about AOCI Components |  |  | 
Cash flow hedging items |  |  | 
Commodity contracts | Cost of sales | $5.1 | $1.8
Foreign exchange contracts | Net sales | 1.0 | (1.0)
Forward interest rate swaps | Interest expense | 0.4 | 0.4
 | Total before tax | 6.5 | 1.2
 | Tax expense | (1.6) | (0.4)
 | Net of tax | $4.9 | $0.8
Amortization of pension and other postretirement benefit plan items |  |  | 
Net actuarial loss | (b) | $(12.0) | $(16.4)
Prior service cost | (b) | 3.1 | 3.1
 | Total before tax | (8.9) | (13.3)
 | Tax benefit | 2.1 | 4.4
 | Net of tax | $(6.8) | $(8.9)


Question: In which year was the amount of tax benefit larger?
Answer: 2018
Calculation: 4.4>2.1
NOTE 23. EXPENSES BY NATURE
Research and development consists of the following:
The impairment expenses in 2018 and 2019 are related to customer specific projects.
The Company’s operations in the Netherlands, Belgium and the United States receive research and development grants and credits from various sources.
Table:
 | Year ended December 31, | 
 | 2018 | 2019
Research and development expenses | 125,280 | 150,745
Capitalization of development expenses | (49,688) | (60,202)
Amortization of capitalized development expenses | 12,039 | 15,597
Research and development grants and credits | (321) | (49)
Total research and development expenses | 87,310 | 106,091
Impairment of research and development related assets | 1,278 | 4,755
Total | 88,588 | 110,846


Question: What is the change in total Research and development expenses?
Answer: 22258
Calculation: 110,846-88,588
Note 17. Other Accrued Expenses and Current Liabilities
Other accrued expenses and current liabilities consisted of the following (in thousands):
Table:
 | December 31, | 
 | 2019 | 2018
Accrued purchases | $4,328 | $1,679
Accrued legal and professional fees | 3,860 | 3,380
Accrued customer-acquisition advertising costs (Note 1) | 3,745 | 2,831
Deferred Symphony acquisition purchase price (Note 4) | 3,517 | 3,394
Accrued roadside assistance claim costs | 1,709 | 1,330
Accrued telephone charges | 1,605 | 2,000
Financial derivatives (Note 12) | 251 | 2,859
Accrued restructuring (Note 5) | 56 | 976
Accrued rent (Note 3) | — | 3,283
Other | 10,259 | 9,503
 | $29,330 | $31,235


Question: What was the amount of Accrued purchases in 2019?
Answer: $4,328
The credit risk profile of trade receivables
Other than those disclosed above no other impairment losses on receivables and contract assets arising from contracts with customers have been recognised. Other than trade receivables there are no financial assets that are past their due date at 31st December 2019.
Payment terms across the Group vary dependent on the geographic location of each operating company. Payment is typically due between 20 and 90 days after the invoice is issued.
All contracts with customers do not contain a significant financing component.
The movement in the allowance for impairment in respect of trade receivables during the year was as follows:
Table:
 | 2019 | 2018
 | £m | £m
Balance at 1st January | 9.8 | 9.6
Additional impairment | 8.6 | 2.8
Amounts written off as uncollectable | (1.2) | (0.7)
Amounts recovered | (0.6) | (0.5)
Impairment losses reversed | (1.1) | (1.4)
Exchange differences | (0.7) | –
Balance at 31st December | 14.8 | 9.8


Question: What was the percentage change in the balance at 31st December in 2019 from 2018?
Answer: 51.02
Calculation: (14.8-9.8)/9.8
16. Net Loss Per Share
Basic earnings per share is calculated by dividing net income by the weighted average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of options, warrants and unvested restricted stock. Dilutive earnings per share is calculated by dividing net income by the weighted average number of common shares used in the basic earnings per share calculation plus the dilutive effect of shares subject to options, warrants and unvested restricted stock.
The following table presents the calculation of basic and diluted net loss per share (in thousands, except per share data):
Potentially dilutive common shares from employee incentive plans are determined by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding restricted stock units, and the assumed issuance of common stock under the ESPP. Weighted stock options outstanding with an exercise price higher than the Company's average stock price for the periods presented are excluded from the calculation of diluted net loss per share since the effect of including them would have been anti-dilutive due to the net loss position of the Company during the periods presented.
Table:
 |  | Year Ended | 
 | June 30,
2019 | June 30,
2018 | June 30,
2017
Net loss | $(25,853) | $(46,792) | $(1,744)
Weighted-average shares used in per share calculation - basic and diluted | 117,954 | 114,221 | 108,273
Net loss per share - basic and diluted | $(0.22) | $(0.40) | $(0.02)


Question: How were Potentially dilutive common shares from employee incentive plans determined?
Answer: by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding restricted stock units, and the assumed issuance of common stock under the ESPP
Diluted earnings per share. Diluted earnings per share for fiscal 2019 and 2018, as well as information as to the effects of special events that occurred in the indicated periods, as previously discussed and detailed below, were as follows (dollars in millions):
(1) We believe the non-GAAP presentation of diluted earnings per share excluding special tax items, consisting of those related to Tax Reform and a change in our permanent reinvestment assertions related to undistributed earnings of two foreign subsidiaries, as well as restructuring costs and the one-time employee bonus, provide additional insight over the change from the comparative reporting periods by eliminating the effects of special or unusual items. In addition, the Company believes that its diluted earnings per share, as adjusted, enhances the ability of investors to analyze the Company’s operating performance and supplements, but does not replace, its diluted earnings per share calculated in accordance with U.S. GAAP.
Diluted earnings per share increased to $3.50 in fiscal 2019 from $0.38 in fiscal 2018 primarily as a result of increased net income due to the factors discussed above and a reduction in diluted shares outstanding due to repurchase activity under the Company's stock repurchase plans.
Table:
 | 2019 | 2018
Diluted earnings per share, as reported (GAAP) | $3.50 | $0.38
Restructuring costs, net of tax  | 0.05 | —
U.S. Tax Reform  | 0.23 | 2.46
Accumulated foreign earnings assertion  | (0.35) | 
One-time employee bonus, net of tax  | — | 0.39
Diluted earnings per share, as adjusted (non-GAAP) (1) | $3.43 | $3.23


Question: What was the amount of U.S. Tax Reform in 2019?
Answer: 0.23
Segment Financial Results
Revenues
The following table sets forth revenues by segment for the periods presented (in millions):
(1) Revenues for Corporate and Other represent deferred revenue purchase accounting adjustments recorded in accordance with GAAP.
Table:
 | Year ended December 31 |  | Variance | 
 | 2019 | 2018 | $ | %
Software Solutions | $1,012.3 | $962.0 | $50.3 | 5%
Data and Analytics | 165.4 | 154.5 | 10.9 | 7%
Corporate and Other (1) | (0.5) | (2.5) | 2.0 | NM
Total | $1,177.2 | $1,114.0 | $63.2 | 6%


Question: What was the average total revenue between 2018 and 2019?
Answer: 1145.6
Calculation: (1,177.2+1,114.0)/2
Adjusted EBITDA Non-GAAP Reconciliation
(UNAUDITED)
($ in millions)
(1) Refer to Non-GAAP Integration and Transformation Costs and Special Items table for details of the integration and transformation costs and special items included above.
Table:
 |  |  | Pro Forma (1)
 | 2019 | 2018 | 2017
Net income (loss) | $(5,269) | (1,733) | 1,508
Income tax expense | 503 | 170 | (770)
Total other expense, net | 2,040 | 2,133 | 2,147
Depreciation and amortization expense | 4,829 | 5,120 | 5,125
Share-based compensation expenses | 162 | 186 | 238
Goodwill impairment | 6,506 | 2,726 | 0
Adjusted EBITDA | 8,771 | 8,602 | 8,248
Exclude: transaction related expenses | 0 | 0 | 192
Exclude: integration and transformation costs(1) | 234 | 378 | 164
Exclude: special items(1) | 65 | 60 | 82
Adjusted EBITDA excluding integration and transformation costs and special items | $9,070 | 9,040 | 8,686
Total revenue | $22,401 | 23,443 | 24,128
Adjusted EBITDA Margin | 39.2% | 36.7% | 34.2%
Adjusted EBITDA Margin, excluding integration and transformation costs and special items | 40.5% | 38.6% | 36.0%


Question: Which table should be referred to for details of the integration and transformation costs and special items?
Answer: Non-GAAP Integration and Transformation Costs and Special Items table
NOTE L – INCOME TAXES
On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, the following that impact the Company: (1) reducing the U.S. federal corporate income tax rate from 35 percent to 21 percent; (2) eliminating the corporate alternative minimum tax; (3) creating a new limitation on deductible interest expense; (4) limiting the deductibility of certain executive compensation; and (5) limiting certain other deductions.
The Company follows ASC 740-10 “Income Taxes” which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.
A reconciliation of tax expense computed at the statutory federal tax rate on loss from operations before income taxes to the actual income tax (benefit) /expense is as follows:
Table:
 | 2019 | 2018
Tax benefit computed at the statutory rate | $(427,244) | $(631,497)
State taxes | 6,525 | 6,874
Book expenses not deductible for tax purposes | 2,980 | 2,882
Rate Change | 45,656 | –
Other | 2,517 | (27,286)
 | (369,566) | (649,027)
Change in valuation allowance for deferred tax assets | 269,203 | 658,650
Income tax (benefit) expense | $(100,363) | $9,623


Question: What is the change in valuation allowance for deferred tax assets in 2018?
Answer: 658,650
humana inc . notes to consolidated financial statements 2014 ( continued ) 15 . stockholders 2019 equity as discussed in note 2 , we elected to early adopt new guidance related to accounting for employee share-based payments prospectively effective january 1 , 2016 . the adoption of this new guidance resulted in the recognition of approximately $ 20 million of tax benefits in net income in our consolidated statement of income for the three months ended march 31 , 2016 that had previously been recorded as additional paid-in capital in our consolidated balance sheet . dividends the following table provides details of dividend payments , excluding dividend equivalent rights , in 2014 , 2015 , and 2016 under our board approved quarterly cash dividend policy : payment amount per share amount ( in millions ) .

Table:
paymentdate | amountper share | totalamount ( in millions )
2014 | $ 1.10 | $ 170
2015 | $ 1.14 | $ 170
2016 | $ 1.16 | $ 172
under the terms of the merger agreement , we agreed with aetna that our quarterly dividend would not exceed $ 0.29 per share prior to the closing or termination of the merger .
on october 26 , 2016 , the board declared a cash dividend of $ 0.29 per share that was paid on january 27 , 2017 to stockholders of record on january 12 , 2017 , for an aggregate amount of $ 43 million .
on february 14 , 2017 , following the termination of the merger agreement , the board declared a cash dividend of $ 0.40 per share , to be paid on april 28 , 2017 , to the stockholders of record on march 31 , 2017 .
declaration and payment of future quarterly dividends is at the discretion of our board and may be adjusted as business needs or market conditions change .
stock repurchases in september 2014 , our board of directors replaced a previous share repurchase authorization of up to $ 1 billion ( of which $ 816 million remained unused ) with an authorization for repurchases of up to $ 2 billion of our common shares exclusive of shares repurchased in connection with employee stock plans , which expired on december 31 , 2016 .
under the share repurchase authorization , shares may have been purchased from time to time at prevailing prices in the open market , by block purchases , through plans designed to comply with rule 10b5-1 under the securities exchange act of 1934 , as amended , or in privately-negotiated transactions ( including pursuant to accelerated share repurchase agreements with investment banks ) , subject to certain regulatory restrictions on volume , pricing , and timing .
pursuant to the merger agreement , after july 2 , 2015 , we were prohibited from repurchasing any of our outstanding securities without the prior written consent of aetna , other than repurchases of shares of our common stock in connection with the exercise of outstanding stock options or the vesting or settlement of outstanding restricted stock awards .
accordingly , as announced on july 3 , 2015 , we suspended our share repurchase program. .

Question: considering the year 2014 , what is the amount of issued shares , in millions?
Answer: 154.54
Calculation: divide(170, 1.10)
the diluted earnings per share calculation excludes stock options , sars , restricted stock and units and performance units and stock that were anti-dilutive . shares underlying the excluded stock options and sars totaled 2.6 million , 10.3 million and 10.2 million for the years ended december 31 , 2017 , 2016 and 2015 , respectively . for the year ended december 31 , 2016 , 4.5 million shares of restricted stock and restricted stock units and performance units and performance stock were excluded . 10 . supplemental cash flow information net cash paid for interest and income taxes was as follows for the years ended december 31 , 2017 , 2016 and 2015 ( in thousands ) : .

Table:
 | 2017 | 2016 | 2015
interest net of capitalized interest | $ 275305 | $ 252030 | $ 222088
income taxes net of refunds received | $ 188946 | $ -39293 ( 39293 ) | $ 41108
eog's accrued capital expenditures at december 31 , 2017 , 2016 and 2015 were $ 475 million , $ 388 million and $ 416 million , respectively .
non-cash investing activities for the year ended december 31 , 2017 included non-cash additions of $ 282 million to eog's oil and gas properties as a result of property exchanges .
non-cash investing activities for the year ended december 31 , 2016 included $ 3834 million in non-cash additions to eog's oil and gas properties related to the yates transaction ( see note 17 ) .
11 .
business segment information eog's operations are all crude oil and natural gas exploration and production related .
the segment reporting topic of the asc establishes standards for reporting information about operating segments in annual financial statements .
operating segments are defined as components of an enterprise about which separate financial information is available and evaluated regularly by the chief operating decision maker , or decision-making group , in deciding how to allocate resources and in assessing performance .
eog's chief operating decision-making process is informal and involves the chairman of the board and chief executive officer and other key officers .
this group routinely reviews and makes operating decisions related to significant issues associated with each of eog's major producing areas in the united states , trinidad , the united kingdom and china .
for segment reporting purposes , the chief operating decision maker considers the major united states producing areas to be one operating segment. .

Question: what is the increase observed in accrued capital expenditures during 2016 and 2017?
Answer: 22.42%
Calculation: divide(475, 388), subtract(#0, const_1)
At the balance sheet date, the combined principal accounting assumptions were as follows:
For the smaller overseas schemes the discount rate used was 1.50% (2017/18: 1.80%) and future pension increases were 1.30% (2017/18: 1.45%).
At 30 March 2019 and 31 March 2018, the discount rate was derived based on a bond yield curve expanded to also include bonds rated AA by one credit agency (and which might for example be rated A or AAA by other agencies).
Table:
 | At 30 Mar 2019 |  | At 31 Mar 2018 | 
 | Premier schemes | RHM schemes | Premier schemes | RHM schemes
Discount rate | 2.45% | 2.45% | 2.70% | 2.70%
Inflation – RPI | 3.25% | 3.25% | 3.15% | 3.15%
Inflation – CPI | 2.15% | 2.15% | 2.05% | 2.05%
Expected salary increases | n/a | n/a | n/a | n/a
Future pension increases | 2.10% | 2.10% | 2.10% | 2.10%


Question: What is the change in the inflation - CPI for RHm schemes from 2018 to 2019?
Answer: 0.1
Calculation: 2.15% - 2.05%
As of December 31, 2019 and 2018, the fair value of the 2022 Notes, which was determined based on inputs that are observable in the market or that could be derived from, or corroborated with, observable market data, quoted price of the 2022 Notes in an over-the-counter market (Level 2), and carrying value of debt instruments (carrying value excludes the equity component of the Company’s convertible notes classified in equity) were as follows (in thousands):
In connection with the issuance of the 2022 Notes, the Company entered into capped call transactions with certain counterparties affiliated with the initial purchasers and others. The capped call transactions are expected to reduce potential dilution of earnings per share upon conversion of the 2022 Notes.
Under the capped call transactions, the Company purchased capped call options that in the aggregate relate to the total number of shares of the Company’s common stock underlying the 2022 Notes, with an initial strike price of approximately $33.71 per share, which corresponds to the initial conversion price of the 2022 Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the 2022 Notes, and have a cap price of approximately $47.20.
The cost of the purchased capped calls of $12.9 million was recorded to shareholders’ equity and will not be re-measured.
Based on the closing price of the Company’s common stock of $78.08 on December 31, 2019, the if-converted value of the 2022 Notes was more than their respective principal amounts.
Table:
 |  | As of December 31, |  | 
 | 2019 |  | 2018 | 
 | Fair Value | Carrying Value | Fair Value | Carrying Value
2022 Notes | $215,801 | $79,224 | $ 189,802 | $94,097


Question: What was the cost of the purchased capped calls?
Answer: The cost of the purchased capped calls of $12.9 million was recorded to shareholders’ equity and will not be re-measured.
The Company had gross unrecognized tax benefits of $15.7 million and $3.0 million, as of June 30, 2019 and June 30, 2018, respectively. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense.
The Company files income tax returns in various federal, state, and local jurisdictions including the United States, Canada, United Kingdom and France. In the normal course of business, the Company is subject to examination by taxing authorities throughout the world. With few exceptions, the Company is no longer subject to income tax examinations by tax authorities in major tax jurisdictions for years before 2014.
Table:
 | June 30, | 
 | 2019 | 2018
 | in millions) | 
Balance at beginning of year | $3.0 | $0.2
Additions for current year tax positions | 1.5 | 1.2
Additions for prior year tax positions | 11.5 | 1.7
Reductions as a result of settlement with tax authority | (0.3) | (0.1)
Balance at end of year | $15.7 | $3.0
Interest and penalties included in balance | $2.2 | $0.1
Amount, if recognized, would impact the effective income tax rate | 10.0 | 1.8
Amount that could be settled within the next year | 10.0 | 1.9


Question: Where does the company file income tax returns?
Answer: in various federal, state, and local jurisdictions including the United States, Canada, United Kingdom and France.
Stock-based Compensation
The following table summarizes stock-based compensation expense related to RSUs, stock options, and ESPP shares for the fiscal years ended September 30, 2019, 2018, and 2017, which were allocated as follows (amounts shown in thousands):
Table:
 | 2019 | 2018 | 2017
Cost of revenue | $207 | $78 | $52
Selling and marketing | 2,967 | 2,656 | 1,577
Research and development | 2,013 | 1,801 | 1,028
General and administrative | 4,450 | 4,415 | 2,821
Stock-based compensation expense included in expenses | $9,637 | $8,950 | $5,478


Question: What is the stock-based compensation expenses for selling and marketing in 2018?
Answer: 2,656
No deferred tax assets were capitalised for the following tax loss carry-forwards and interest carry-forwards or temporary differences because realisation of the assets in the short-to-medium term is not expected:
The loss carry-forwards as of the closing date predominantly concern the German consolidation group. They can be carried forward without limitation.
Table:
€ million | 30/9/2018 | 30/9/2019
Corporate tax losses | 4,320 | 4,883
Trade tax losses | 3,296 | 3,679
Interest carry-forwards | 57 | 83
Temporary differences | 104 | 120


Question: In which year were the temporary differences larger?
Answer: 2019
Calculation: 120>104